Assessing the Validity and Reliability of Tooth Widths and Bolton Ratios Obtained from Digital Models and Plaster Models.

Aim: The aim of the study is to compare and evaluate the validity and reliability of tooth widths and Bolton ratios measured from digital models obtained from intraoral scanners and plaster models derived from alginate and polyvinyl siloxane impression materials.

Materials And Methods: Alginate and polyvinylsiloxane impression was taken for 40 subjects, orthokal stone was poured and grouped as Group I and Group II, respectively. Intraoral scanning was done using Trios Pod 3shape for the same patients, digital models were obtained and grouped as Group III.

Effect of 50% hydro-ethanolic leaf extracts of ruellia tuberosa L. And dipteracanthus patulus (jacq.) on lipid profile in alloxan induced diabetic rats.

Background: The study was undertaken to investigate the effect of 50% hydro -ethanolic leaf extracts of Ruellia tuberosa L. and Dipteracanthus patulus (Jacq.) on lipid profile in alloxan induced diabetic rats.

Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.

Shigellosis is a leading cause of diarrhea worldwide prompting vaccine development. The Shigella flexneri Invaplex 50 is a macromolecular complex containing IpaB, IpaC, and LPS, formulated from an aqueous extract of virulent Shigella delivered via nasal administration. Preclinical vaccine testing demonstrated safety, immunogenicity and efficacy.

L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets.

Newborn piglets develop pulmonary hypertension and have diminished pulmonary vascular nitric oxide (NO) production when exposed to chronic hypoxia. NO is produced by endothelial NO synthase (eNOS) in the pulmonary vascular endothelium using l-arginine as a substrate and producing l-citrulline as a byproduct. l-Citrulline is metabolized to l-arginine by two enzymes that are colocated with eNOS in pulmonary vascular endothelial cells.

Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.

An oral, microencapsulated anti-colonization factor 6 antigen (meCS6) vaccine, with or without heat-labile enterotoxin with mutation R192G (LT(R192G)) (mucosal adjuvant), against enterotoxigenic Escherichia coli (ETEC) was evaluated for regimen and adjuvant effects on safety and immunogenicity. Sixty subjects were enrolled into a three-dose, 2-week interval or four-dose, 2-day interval regimen. Each regimen was randomized into two equal groups of meCS6 alone (1 mg) or meCS6 with adjuvant (2 microg of LT(R192G)).